603883.SH
老百姓
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 13.01
−1.44%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 22.3B | 22.2B | 22.4B | 22.4B | 20.2B |
| Cost of Revenue | 15.1B | 15.1B | 14.9B | 15.1B | 13.7B |
| Gross Profit | 7.2B | 7.2B | 7.4B | 7.3B | 6.4B |
| Operating Expenses | |||||
| R&D Expense | 54.8M | 51.1M | 2.0M | 2.5M | 2.2M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 1.3B | 1.3B | 1.3B | 1.2B | 1.1B |
| Selling & Marketing Expense | 4.7B | 4.7B | 4.9B | 4.6B | 3.9B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 6.2B | 6.2B | 6.5B | 6.0B | 5.3B |
| Cost and Expenses | 21.3B | 21.3B | 21.4B | 21.1B | 19.0B |
| Operating Income (EBIT) | 763.9M | 741.9M | 913.6M | 1.4B | 1.2B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 775.7M | 756.2M | 916.0M | 1.4B | 1.2B |
| Income Tax Expense | 220.7M | 215.7M | 230.9M | 284.3M | 231.4M |
| Bottom Line | |||||
| Net Income | 395.1M | 381.8M | 519.1M | 929.0M | 785.0M |
| Earnings from Cont. Ops | 555.1M | 540.4M | 685.1M | 1.1B | 976.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 395.1M | 381.8M | 519.1M | 929.0M | 785.0M |
| Per Share | |||||
| Basic EPS | CN¥0.52 | CN¥0.50 | CN¥0.68 | CN¥1.23 | CN¥1.36 |
| Diluted EPS | CN¥0.52 | CN¥0.50 | CN¥0.68 | CN¥1.23 | CN¥1.36 |
| Revenue Per Share | CN¥29.56 | CN¥29.12 | CN¥29.29 | CN¥29.71 | CN¥34.96 |
| Shares | |||||
| Basic Shares Outstanding | 753.9M | 763.7M | 763.3M | 755.3M | 577.2M |
| Diluted Shares Outstanding | 753.9M | 763.7M | 763.3M | 755.3M | 577.2M |
| Profitability Metrics | |||||
| EBITDA | — | 1.2B | 1.3B | 1.7B | 1.5B |
| D&A | — | 446.9M | 422.3M | 325.4M | 292.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026